Zhijian He

3.5k total citations · 1 hit paper
35 papers, 2.6k citations indexed

About

Zhijian He is a scholar working on Molecular Biology, Oncology and Biomaterials. According to data from OpenAlex, Zhijian He has authored 35 papers receiving a total of 2.6k indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Molecular Biology, 9 papers in Oncology and 6 papers in Biomaterials. Recurrent topics in Zhijian He's work include Lipoproteins and Cardiovascular Health (4 papers), Nanoparticle-Based Drug Delivery (4 papers) and Cancer Treatment and Pharmacology (4 papers). Zhijian He is often cited by papers focused on Lipoproteins and Cardiovascular Health (4 papers), Nanoparticle-Based Drug Delivery (4 papers) and Cancer Treatment and Pharmacology (4 papers). Zhijian He collaborates with scholars based in China, United States and Germany. Zhijian He's co-authors include Alexander V. Kabanov, Marina Sokolsky‐Papkov, Evgeniya G. Plotnikova, Elena V. Batrakova, Aleksandr Piroyan, Matthew J. Haney, Tejash Patel, Richa Gupta, Natalia L. Klyachko and Yuling Zhao and has published in prestigious journals such as Blood, Biomaterials and Biochemical Journal.

In The Last Decade

Zhijian He

34 papers receiving 2.6k citations

Hit Papers

Exosomes as drug delivery vehicles for Parkinson's diseas... 2015 2026 2018 2022 2015 500 1000 1.5k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Exosomes as drug delivery vehicles for Parkinson's disease therapy
    2015 1.6k citations Zhijian He, Marina Sokolsky‐Papkov et al. profile →

Peers

Zhijian He
Marcel H.A.M. Fens Netherlands
Shuhua Bai United States
George Mattheolabakis United States
Shuang Dou China
Jia Lv China
Xiaohui Fu China
Hae Yun Nam South Korea
Xiaoru Shao China
Yingjuan Lu United States
Marcel H.A.M. Fens Netherlands
Zhijian He
Citations per year, relative to Zhijian He Zhijian He (= 1×) peers Marcel H.A.M. Fens

Countries citing papers authored by Zhijian He

Since Specialization
Citations

This map shows the geographic impact of Zhijian He's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Zhijian He with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Zhijian He more than expected).

Fields of papers citing papers by Zhijian He

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Zhijian He. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Zhijian He. The network helps show where Zhijian He may publish in the future.

Co-authorship network of co-authors of Zhijian He

This figure shows the co-authorship network connecting the top 25 collaborators of Zhijian He. A scholar is included among the top collaborators of Zhijian He based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Zhijian He. Zhijian He is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Wang, Xiaomin, et al.. (2024). Integrative approach using network pharmacology, bioinformatics, and experimental methods to explore the mechanism of cantharidin in treating colorectal cancer. Naunyn-Schmiedeberg s Archives of Pharmacology. 397(9). 6745–6761. 1 indexed citations
2.
3.
He, Zhijian, Xuyang Song, Cecil Chen, et al.. (2023). Population Pharmacokinetics and Exposure–Response Analysis of Tremelimumab 300 mg Single Dose Combined with Durvalumab 1500 mg Q4W (STRIDE) in Patients with Unresectable Hepatocellular Carcinoma. The Journal of Clinical Pharmacology. 63(11). 1221–1231. 4 indexed citations
4.
He, Zhijian, Vincent Duval, António Gonçalves, et al.. (2023). Population Pharmacokinetics and Exposure–Response Analysis for the CTLA‐4 Inhibitor Tremelimumab in Metastatic NSCLC Patients in the Phase III POSEIDON Study. Clinical Pharmacology & Therapeutics. 114(6). 1375–1386. 2 indexed citations
5.
Zhang, Jie, Jingjing Huang, Hongwei Li, et al.. (2023). Proteomic and functional analysis of HDL subclasses in humans and rats: a proof-of-concept study. Lipids in Health and Disease. 22(1). 86–86. 6 indexed citations
6.
Xin, Lei, Rui Ji, Tianyu Wei, et al.. (2023). Integrated analysis of single-cell transcriptome and structural biology approach reveals the dynamics changes of NP subtypes and roles of Menaquinone in attenuating intervertebral disc degeneration. Journal of Biomolecular Structure and Dynamics. 42(18). 9439–9462. 1 indexed citations
7.
Li, Weihang, Yongchun Wang, Zhijian He, et al.. (2023). Deciphering the sequential changes of monocytes/macrophages in the progression of IDD with longitudinal approach using single-cell transcriptome. Frontiers in Immunology. 14. 1090637–1090637. 17 indexed citations
8.
Jackson, Christopher, Eva Segelov, Hans Prenen, et al.. (2021). Oral paclitaxel with encequidar compared to intravenous paclitaxel in patients with advanced cancer: A randomised crossover pharmacokinetic study. British Journal of Clinical Pharmacology. 87(12). 4670–4680. 11 indexed citations
9.
Wu, Xiaoying, Zhijian He, Junjie Wang, et al.. (2021). Large HDL2 combined with inflammatory factors as superior predictors for coronary artery disease than small HDL3. Annals of Translational Medicine. 9(8). 672–672. 2 indexed citations
10.
Pan, Zhi‐Yong, Yanjun Wu, Lin Hao, et al.. (2021). Pooled Analysis of the Accuracy of Xpert Ebola Assay for Diagnosing Ebola Virus Infection. BioMed Research International. 2021(1). 5527505–5527505. 3 indexed citations
11.
He, Zhijian, et al.. (2021). Evaluation of Xpert Carba‐R Assay for the Detection of Carbapenemase Genes in Gram‐Negative Bacteria. BioMed Research International. 2021(1). 6614812–6614812. 11 indexed citations
12.
13.
He, Zhijian, et al.. (2020). Evaluation of Xpert MTB/RIF for the Diagnosis of Lymphatic Tuberculosis. BioMed Research International. 2020(1). 1968487–1968487. 3 indexed citations
14.
Liu, Zihao, Wanbing He, Bingqing Deng, et al.. (2019). CC chemokine receptor 2 functions in osteoblastic transformation of valvular interstitial cells. Life Sciences. 228. 72–84. 16 indexed citations
15.
16.
Kao, Kenneth R., et al.. (2017). PYGOPUS2 expression in prostatic adenocarcinoma is a potential risk stratification marker for PSA progression following radical prostatectomy. Journal of Clinical Pathology. 71(5). 402–411. 6 indexed citations
17.
He, Zhijian, Xiaomeng Wan, Anita Schulz, et al.. (2016). A high capacity polymeric micelle of paclitaxel: Implication of high dose drug therapy to safety and in vivo anti-cancer activity. Biomaterials. 101. 296–309. 159 indexed citations
18.
Du, Ran, Liang‐Liang Fan, Minjie Lin, et al.. (2016). Mutation detection in Chinese patients with familial hypercholesterolemia. SpringerPlus. 5(1). 2095–2095. 3 indexed citations
19.
He, Zhijian, Lei Miao, Rainer Jordan, et al.. (2015). A Low Protein Binding Cationic Poly(2‐oxazoline) as Non‐Viral Vector. Macromolecular Bioscience. 15(7). 1004–1020. 38 indexed citations
20.
Luxenhofer, Robert, Yingchao Han, Anita Schulz, et al.. (2012). Poly(2‐oxazoline)s as Polymer Therapeutics. Macromolecular Rapid Communications. 33(19). 1613–1631. 390 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Marcel H.A.M. Fens Breakdown of academic impact, for papers by Shuhua Bai Breakdown of academic impact, for papers by George Mattheolabakis Breakdown of academic impact, for papers by Shuang Dou Breakdown of academic impact, for papers by Jia Lv Breakdown of academic impact, for papers by Xiaohui Fu Breakdown of academic impact, for papers by Hae Yun Nam Breakdown of academic impact, for papers by Xiaoru Shao Breakdown of academic impact, for papers by Yingjuan Lu
Rankless by CCL
2026